Patents by Inventor Jonathan Pachter

Jonathan Pachter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250049792
    Abstract: The present disclosure relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor, in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, and a KRAS G12C inhibitor, and optionally a FAK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: July 27, 2022
    Publication date: February 13, 2025
    Inventors: Silvia Coma, Jonathan A. Pachter, Brian M. Stuglik, Julian Downward, Miriam Molina Arcas
  • Publication number: 20250009746
    Abstract: Combinations of compounds as described herein, a BRAF V600 inhibitor, a pan-RAF inhibitor, a CRAF inhibitor, or a RAF inhibitor, and a dual RAF/MEK inhibitor, can be used, for example, in methods of treating abnormal cell growth/cancers in a subject in need thereof.
    Type: Application
    Filed: October 27, 2022
    Publication date: January 9, 2025
    Inventors: Jonathan A. Pachter, Sanjib Chowdhury, Silvia Coma
  • Publication number: 20240382485
    Abstract: The present disclosure provides, in part, methods of reducing the severity of or preventing toxicity or an adverse event associated with administration of a dual RAF/MEK inhibitor in a subject, comprising administering to the subject an effective amount of the dual RAF/MEK inhibitor, an effective amount of an antibiotic agent, and optionally an effective amount of a corticosteroid.
    Type: Application
    Filed: November 2, 2022
    Publication date: November 21, 2024
    Inventors: BRIAN M. STUGLIK, ANDREW KOUSTENIS, JONATHAN A. PACHTER, SILVIA COMA
  • Publication number: 20240115571
    Abstract: The present invention relates to methods, compositions, and oral dosage forms of a SHP2 inhibitor, a SOS1 inhibitor, an ERK1/2 inhibitor, a CDK4/6 inhibitor, an AKT inhibitor, an mTOR inhibitor, a pan-HER inhibitor, or an EGFR inhibitor in combination with a MEK inhibitor or a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: February 4, 2022
    Publication date: April 11, 2024
    Inventors: Silvia COMA, Jonathan A. PACHTER, Sanjib CHOWDHURY
  • Publication number: 20240000790
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Application
    Filed: December 21, 2022
    Publication date: January 4, 2024
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • Publication number: 20230330088
    Abstract: The present invention relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: July 13, 2021
    Publication date: October 19, 2023
    Inventors: Silvia COMA, Jonathan A. PACHTER
  • Publication number: 20230321097
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: November 17, 2022
    Publication date: October 12, 2023
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
  • Publication number: 20230293534
    Abstract: Provided herein, at least in part, are methods of treating a hematologic malignancy in a human subject in need thereof, comprising orally administering to the subject duvelisib or a pharmaceutically acceptable form thereof.
    Type: Application
    Filed: July 24, 2020
    Publication date: September 21, 2023
    Inventors: Daniel PATERSON, Jonathan A. PACHTER, Hagop YOUSSOUFIAN, Stephanie LUSTGARTEN
  • Publication number: 20230201198
    Abstract: The present invention relates to methods for treating abnormal cell growth (e.g., cancer) in a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) comprising administering to the subject an effective amount of a MEK inhibitor (e.g., a dual RAF/MEK inhibitor) alone or in combination with an additional agent.
    Type: Application
    Filed: April 27, 2021
    Publication date: June 29, 2023
    Inventors: Jonathan A. PACHTER, Daniel PATERSON, Brian M. STUGLIK
  • Publication number: 20230103007
    Abstract: The present invention relates to methods, compositions, and oral dosage forms of a KRAS G12C inhibitor in combination with a FAK inhibitor and/or a MEK. inhibitor or a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: January 28, 2021
    Publication date: March 30, 2023
    Inventors: Jonathan A. PACHTER, Silvia COMA
  • Patent number: 11564927
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: January 31, 2023
    Assignee: Verastem, Inc.
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • Publication number: 20220387491
    Abstract: The present disclosure relates generally to methods of making immune effector cells, such as those engineered to express a Chimeric Antigen Receptor (CAR) including CAR-T cells, and compositions comprising the same, for use in treating cancer.
    Type: Application
    Filed: November 4, 2020
    Publication date: December 8, 2022
    Inventors: Jonathan A. PACHTER, Silvia COMA
  • Publication number: 20210338681
    Abstract: Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or a pharmaceutically acceptable form thereof, in combination with a CD47 inhibitor, or a pharmaceutically acceptable form thereof in the presence or absence of an opsonizing antibody. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer.
    Type: Application
    Filed: October 1, 2019
    Publication date: November 4, 2021
    Inventors: Jonathan A. PACHTER, Shawn LELAND
  • Publication number: 20200330471
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Application
    Filed: November 25, 2019
    Publication date: October 22, 2020
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • Publication number: 20200147080
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: July 23, 2019
    Publication date: May 14, 2020
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
  • Patent number: 10532056
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: January 14, 2020
    Assignee: Verastem, Inc.
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • Patent number: 10406158
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: September 10, 2019
    Assignee: Verastem, Inc.
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
  • Publication number: 20190046531
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: April 2, 2018
    Publication date: February 14, 2019
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
  • Publication number: 20180177788
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Application
    Filed: June 29, 2016
    Publication date: June 28, 2018
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • Patent number: 9962385
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: May 8, 2018
    Assignee: Verastem, Inc.
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu